Report Conveys Value and Threats of Nanotechnology Research
|
By LabMedica International staff writers Posted on 04 Feb 2013 |
While scientists constantly increase their knowledge of biology and the surrounding world, all this newly gleaned information has the potential to advance healthcare, it is also possible that the same discoveries can also be used in ways that cause extensive havoc.
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
Latest BioResearch News
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








